Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Gottlieb Pushing 'Seamless' Clinical Trials For Faster Development

Executive Summary

US FDA Commissioner notes that combined-phase clinical trials could be expanded beyond oncology as one way of reducing drug development costs.

Advertisement

Related Content

Historic Output Of Disease-Specific Guidances Is Among Gottlieb's Legacies At US FDA
Platform Trials Could Be A Solution To Expanded Access, Woodcock Says
Real-World Evidence Could Speed Development Of Drugs Offering Incremental Improvements
Keeping Track: Shionogi, Fresenius Kabi Join July Approval Parade; Busy August Expected
US FDA's Gottlieb Touts 'Seamless' Clinical Trials, Worries About Second-To-Market Products
Hypertension Drug Development To Be Streamlined Under US FDA Guidance
Disease-Specific Drug Development Guidances Coming From US FDA In 2018
Disease-Specific Drug Development Guidances Coming From US FDA In 2018
Latest R&D Spending Benchmark Study Puts Cancer Drug Costs At $648M
Gene Therapy Platforms May Require Less Preclinical Data, Gottlieb Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS121514

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel